New Insights on Alzheimer’s Disease from Harvard Researchers
Researchers at Harvard Medical School have made a significant discovery they think could be at the core of Alzheimer’s disease—a shortage, specifically of lithium, a mineral that’s naturally found in the brain. They’re optimistic that certain medications could not only prevent but also possibly reverse some unstable conditions tied to this disease.
These findings, detailed in a recent study published in Nature, come from a decade’s worth of research that includes examining brain tissue and blood samples from both humans and mice.
They’ve pinpointed that the loss of lithium might be one of the earliest signs of Alzheimer’s onset, and reintroducing it could help maintain brain health. “The idea that a deficiency in lithium could lead to Alzheimer’s is a novel perspective and points to a new avenue for treatment,” said Bruce Yankner, a professor at the Blavatnik Institute at HMS.
In their experiments, mice received lithium orotate, and even older animals with developing conditions showed protection against brain cell damage and a restoration of memory. Yankner expressed that he was particularly impressed by lithium’s broad impact on various symptoms related to Alzheimer’s disease, remarking that he hasn’t seen anything quite like it in his years of research.
Moreover, maintaining adequate lithium levels during childhood may also help prevent the disease’s emergence later in life.
These promising results could lead to refined strategies for early diagnosis, prevention, and even treatment. The study aligns with earlier population research that suggested higher lithium levels in drinking water correlate with reduced dementia rates.
However, Alzheimer’s complexity remains, as even those with amyloid protein buildup may not display cognitive decline, and treatments targeting this accumulation have not been very effective, often only slowing down the progression.
Many factors, both genetic and environmental, contribute to the disease, but scientists are still figuring out why it develops in some and not others. The study authors suggest that lithium could be that crucial piece missing from the puzzle.
“My aspiration is that lithium serves a more foundational role than just the anti-amyloid and anti-tau therapies, potentially reducing cognitive decline and enhancing the quality of life for patients,” said Yankner.
While the team emphasizes the need for confirmation through human trials, they remain hopeful that measuring lithium levels may lead to new avenues for screening and treating Alzheimer’s disease. “It’s important to be cautious when drawing conclusions from mouse studies, but we won’t know until we attempt it in a controlled human context,” Yankner noted. “The results thus far are really encouraging.”
